Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$71 Mln
P/E Ratio
--
P/B Ratio
1.03
Industry P/E
--
Debt to Equity
0.01
ROE
-0.56 %
ROCE
-55.5 %
Div. Yield
0 %
Book Value
1.04
EPS
-0.78
CFO
€-234.61 Mln
EBITDA
€-297.26 Mln
Net Profit
€-266.15 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
InflaRx N.V. - ADR
| -53.85 | -9.52 | -55.12 | -15.56 | -14.44 | -26.04 | -- |
|
BSE Sensex*
| 1.74 | 3.51 | 4.97 | 8.92 | 11.19 | 21.04 | 11.14 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|
|
InflaRx N.V. - ADR
| -47.42 | -34.87 | -5.37 | 27.02 | -89.11 | 73.08 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 3.21 | 702.49 | 3.85 | 18.49 | |
| 4.24 | 517.80 | 26.63 | 3.8 | |
| 14.50 | 762.90 | -- | -49.94 | |
| 1.32 | 119.94 | -- | -42.73 |
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of... autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany. Address: Winzerlaer Str. 2, Jena, Germany, 07745 Read more
Co-Founder, CEO & Executive Director
Dr. Niels C. Riedemann M.D., Ph.D.
Co-Founder, CEO & Executive Director
Dr. Niels C. Riedemann M.D., Ph.D.
Headquarters
Jena
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of InflaRx NV - ADR stood at $ 76 Mln as on 31-Dec-24
The share price of InflaRx NV - ADR is $1.14 (NASDAQ) as of 21-Apr-2025 16:00 EDT. InflaRx NV - ADR has given a return of -14.44% in the last 3 years.
InflaRx NV - ADR has a market capitalisation of $ 71 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of InflaRx NV - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the InflaRx NV - ADR and enter the required number of quantities and click on buy to purchase the shares of InflaRx NV - ADR.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany. Address: Winzerlaer Str. 2, Jena, Germany, 07745
The CEO & director of Dr. Niels C. Riedemann M.D., Ph.D.. is InflaRx NV - ADR, and CFO & Sr. VP is Dr. Niels C. Riedemann M.D., Ph.D..
There is no promoter pledging in InflaRx NV - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
105
|
|
|
91
|
|
|
73
|
|
|
36
|
| InflaRx N.V. - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-56.15
|
|
Operating margin(%)
|
-27769.35
|
|
Net Margin(%)
|
-27784.96
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of InflaRx NV - ADR was $0 Mln.
$0.08
(
